The barriers and solutions to the current prior-authorization (PA) process at an integrated health system were evaluated.
On April 9, a congressional hearing will explore the impact of pharmacy benefit managers on high drug prices. It’s a connection that many heart patients have learned firsthand.
More than 50 percent of Europeans have raised cholesterol, increasing their risk of heart attack, stroke and death – and costing the EU billions every year in health care expenses and lost productivity. So explains a new “Fast Facts” policy brief from the European Alliance for Patient Access, a division of the Global Alliance for Patient Access.
England has a plan. It’s comprehensive, long term and aimed at preventing 150,000 heart attacks and strokes over the next 10 years. How? By, among other measures, reducing high cholesterol, hypertension and atrial fibrillation.
New clinical guidelines for cholesterol treatment could be a good thing for both physicians and patients, so long as they are used properly.
The rising price of insulin has created a multibillion-dollar business for the pharmaceutical oligopoly that controls the market — and a deep sense of anger and fear among people who need the drug to stay alive.
Americans pay more for prescription drugs than any country in the world, and the pharmaceutical industry earns billions in profits each year.
Patient advocates across the country cheered this week as news spread about a decrease in the list price of evolocumab.
Heart disease patients, providers, caregivers and stakeholders agree: Health plan policies that delay access to life-saving medication are unacceptable.
Powerful PCSK9 inhibitors were supposed to revolutionize care for cardiac patients. But insurers and other payers balked at sky-high prices.
A massive stroke marked a serious change in the weather for Mark McEwen, whose familiar face brought viewers the weather forecast on the 1990s’ “CBS This Morning.” McEwen keynoted the May 15 Cardiovascular Health Policy Summit in Washington, DC, describing how he struggled to regain speech, mobility and fine motor skills.
Heart patients in Europe have something to celebrate.
During the first year an expensive class of new cholesterol-lowering drugs was on the market, only one in three patients with a prescription actually received the therapy due to lack of insurance approval and high copays, according to a study sponsored by a manufacturer of one such drug.
Read more at Reuters Health.
STATEMENT FROM KEITH FERDINAND, MD, CARDIOLOGIST:
“ICER’s report is a disappointment for patients and physicians and other practitioners who have seen expected results with these drugs. For patients suffering with extremely high cholesterol, these medications can reduce the risk of heart attack and stroke. Unfortunately, ICER’s report could jeopardize many patient’s ability to access the life-saving medication they and their physicians and other providers have determined is the best course of care.”
A money-back deal for cholesterol-lowering PCSK9 inhibitors doesn’t cut costs enough, claims a new analysis from a University of Pittsburgh researcher. The drug’s manufacturer says the numbers used to calculate her cost figures don’t reflect reality. But the voice that’s missing from this public debate is the one that arguably has the most to lose – patients, who already struggle to access breakthrough cardiovascular therapies.
Access to PCSK9 Inhibitors
Approved by the FDA to treat patients with genetic high cholesterol and those who have already experienced a cardiac event, PCSK9 inhibitors can lower stubborn “bad” cholesterol for patients who’ve found few results with existing treatments. But the drugs’ price point has led health plans to establish extensive prior authorization processes to limit costs. A national IfPA health plan report card found that 43 percent of patients are denied access to the PCSK9 inhibitor their doctor prescribes.
Read more at Institute for Patient Access.
Florida health plans reject nearly 50 percent of claims for treatment
WASHINGTON – On Saturday, August 5, the Partnership to Advance Cardiovascular Health will host a health forum, “Advancing Cardiovascular Health & Patient Access to Innovative Therapies.” The lunchtime event in Orlando at the Florida Medical Association’s annual meeting will bring together patient advocates, clinicians, and policymakers to discuss innovations in cardiovascular therapies, high rates of cardiovascular disease in Florida and barriers that patients face in accessing new cholesterol-lowering drugs. Seth Baum, MD, founder of Excel Medical Clinical Trials and president of the American Society for Preventive Cardiology, will lead the forum.